Contents
15 July 2020
Vol 12, Issue 552
Vol 12, Issue 552
Research Articles
- High-loading Gα13-binding EXE peptide nanoparticles prevent thrombosis and protect mice from cardiac ischemia/reperfusion injury
In vivo high-loading peptide nanoparticle administration prevented thrombosis and myocardial injury without causing bleeding in mice.
- Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance
Macrophage subsets are dynamically altered during glioma response to radiotherapy, and their targeting delays tumor recurrence in preclinical trials.
- STING differentially regulates experimental GVHD mediated by CD8 versus CD4 T cell subsets
STING differentially regulates experimental graft-versus-host disease mediated by distinct T cell subsets.
- Two-miRNA–based finger-stick assay for estimation of absorbed ionizing radiation dose
A circulating microRNA-based biodosimetry assay estimates ionizing radiation dose in mice at a range and time points relevant to human health care.
Focus
- Ethical challenges for pediatric liver organoid transplantation
The authors discuss whether it is ethically acceptable to include children in a first-in-human clinical trial of liver organoid transplantation.
Editors' Choice
- Mapping the tumor frontline
In cutaneous squamous cell carcinoma, a tumor-specific cell type at the leading edge may drive stromal and immune changes that facilitate progression.
- Plasma proteins have a ticket to ride the blood-brain barrier
Analysis of labeled plasma proteins reveals a shift from receptor-mediated brain uptake to less specific transcytosis that occurs with aging.
- Care packages for the bone marrow
Platelets secrete extracellular vesicles that can traffic to the bone marrow and stimulate megakaryopoiesis.
About The Cover
ONLINE COVER Promising Antiplatelet Peptide Particles. The image shows a scanning electron micrograph of an activated platelet. Current antiplatelet drugs are effective against occlusive thrombosis caused by activated platelets but can result in hemorrhage. The peptide mP6 inhibited thrombosis without hemorrhage in preclinical models, but inefficient and impractical delivery hindered its therapeutic use. Pang et al. incorporated modified mP6 in lipid-stabilized, high-loading peptide nanoparticles (HLPNs) and showed increased delivery efficiency compared to mP6 alone. In mouse models, the HLPNs prevented thrombosis without affecting bleeding and prevented cardiac dysfunction and inflammation caused by myocardial ischemia. [CREDIT: STEVE GSCHMEISSENER/SCIENCE SOURCE]
